Bio-Rad Laboratories Inc. (BIO)
NYSE: BIO
· Real-Time Price · USD
286.65
2.00 (0.70%)
At close: Aug 19, 2025, 11:56 AM
0.70% (1D)
| Bid | 285.71 |
| Market Cap | 7.76B |
| Revenue (ttm) | 2.55B |
| Net Income (ttm) | 319.17M |
| EPS (ttm) | 11.08 |
| PE Ratio (ttm) | 25.87 |
| Forward PE | 24.45 |
| Analyst | Buy |
| Ask | 287 |
| Volume | 41,586 |
| Avg. Volume (20D) | 348,182 |
| Open | 286.79 |
| Previous Close | 284.65 |
| Day's Range | 284.97 - 290.26 |
| 52-Week Range | 211.43 - 387.99 |
| Beta | 0.91 |
Analyst Forecast
According to 0 analyst ratings, the average rating for BIO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Bio-Rad Laboratories Inc. is scheduled to release its earnings on
Oct 29, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+17.63%
Bio-Rad Laboratories shares are trading higher aft...
Unlock content with
Pro Subscription
2 weeks ago
-3.25%
Bio-Rad Laboratories shares are trading higher after the company reported better-than-expected Q2 financial results.
2 weeks ago · fool.com
Bio-Rad (BIO) Q2 EPS Jumps 51%Bio-Rad (BIO) Q2 EPS Jumps 51%
2 weeks ago · businesswire.com
Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company's mana...
